\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2020 2020-01-15 (revised: 6 Year 2020 15 January 2020)} \def\TheID{\makeatother } \def\TheDate{2020 2020-01-15} \title{} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Umeaku, Chinyelu Nkiru, Ukoha, Chinwe Clarice, Ebe, Tochukwu Ezechi, Ozo, Chinwe Njideka, Egbuna, Helen Ifeoma, Ibekwe, Maureen Ifeynwa, Chukwuno, Esther Oluchukwu, Okeke, Ugochukwu Chibueze} \affil[1]{ Ojukwu University} \renewcommand\Authands{ and } \date{\small \em Received: 8 December 2019 Accepted: 5 January 2020 Published: 15 January 2020} \maketitle \begin{abstract} Most urinary tract infections are due to Candida species, C. albicans being most prevalent. Laboratory research study was used to examine the prevalence of candidiasis amongst undergraduate students of Chukwuemeka Odumegwu Ojukwu University, Uli. A total of 100 students were investigated. Clean catch midstream urine samples were used for the analysis. Standard microbiological procedures were utilized. A structured questionnaire was issued to each student to obtain their socio-demographic data. Our study found Candida albicans in 14(14%) of the urine samples. Significant candidiasis was strongly associated with being female as higher percentage of the isolates were from female students. Of the 14(14.0%) positive urine samples, 4(28.6%) were from symptomatic students, whereas 10(71.4%) were asymptomatic. \end{abstract} \keywords{candida albicans, candidiasis, urine samples, students} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \par research study was used to examine the prevalence of candidiasis amongst undergraduate students of Chukwuemeka Odumegwu Ojukwu University, Uli. A total of 100 students were investigated. Clean catch midstream urine samples were used for the analysis. Standard microbiological procedures were utilized. A structured questionnaire was issued to each student to obtain their socio-demographic data. Our study found Candida albicans in 14(14\%) of the urine samples. Significant candidiasis was strongly associated with being female as higher percentage of the isolates were from female students. Of the 14(14.0\%) positive urine samples, 4(28.6\%) were from symptomatic students, whereas 10(71.4\%) were asymptomatic. Although candida vulvovaginitis occurs commonly, the reasons for its occurrence and recurrence are often unclear. Several potential risk factors have been described, including the recent use of antibiotics and oral contraceptives, uncontrolled diabetes, increased estrogen levels, impaired immune system, gastrointestinal colonization by the organism, and specific immunological defects. However, the data supporting each of these factors are conflicting, and to date, none are predictive of the infection. This study evaluates the potential risk factors of C. albicans and discusses the implications for clinical practice. We, therefore, recommend that further studies be carried out to determine the definite risk factors of candidiasis. \section[{I. Introduction}]{I. Introduction}\par ulvovaginal candidiasis (VVC) is a fungal or yeast infection. It is found in the lower genital tract, the vulva, and the vagina of females \hyperref[b55]{(Sobel, 2007)}. When this disease is caused by Candida species, it is known as candidiasis or moniliasis. VVC can be recurrent or relapsing \hyperref[b39]{(Nyirjesy and Sobel, 2003)}. This occurs when a female experiences four or more episodes of VVC per year. Asymptomatic infections occur in about 5\% of healthy women {\ref (Reset et al., 2000)}.\par VVC remains a common problem worldwide, affecting all strata of the society. The absence of rapid, simple, and inexpensive diagnostic tests continues to result in both over diagnosis and under diagnosis of VVC. Candida albicans, non-albican species, and immune suppression have led to the development of recurrent diseases, some of which do not respond to conventional antifungal drugs {\ref (Nwadiohaet al., 2013)}.\par According to \hyperref[b33]{McClelland et al. (2009)}, Candida spp. are part of the lower genital tract flora in 20\%-50\% of healthy women. In line with the studies of \hyperref[b53]{Singh (2003)}, C. albicans is the most frequent colonizer and is incriminated in most cases of VVC. Over the last ten years, research evidence has demonstrated an increase in the frequency of cases caused by other species of Candida. C. glabrata is also a leading cause of VVC \hyperref[b47]{(Ray et al., 2007)}. About 75\% of women will experience at least one episode of VVC during their lifetime. 70 -75\% of healthy adult women have had at least one episode of VVC during their reproductive life, and half of the college women will by the age of 25 years have had one case of VVC diagnosed by a physician \hyperref[b55]{(Sobel, 2007)}. VVC is not a sexually transmitted disease, because it also affects children and women who abstain themselves from sexual relationships. However, it can be transmitted sexually (de \hyperref[b12]{Leon et al., 2002)}. Diagnosis of VVC should not be based solely on patient history and a genital examination because of its low specificity of symptoms and signs. In addition, other causes like leukorrhea and pruritus vulvae mimic VVC \hyperref[b19]{(Geiger and Foxman, 2006)}. Therefore, to have a definitive diagnosis of VVC, cultural isolation and identification of Candida spp. are crucial.\par Previous findings have provided data on the prevalence of VVC. It is interesting to note that most previous studies focused on immune compromised subjects, especially pregnant women, diabetics, subjects on broad-spectrum antibiotic therapy, women on oral contraception with high estrogen content, and HIV-positive subjects, with few studies on otherwise immunocompetent women. Interrelationships between Lactobacillus acidophilus and other endogenous flora, estrogen, glycogen, vaginal pH, and metabolic byproducts of these micro biomes determine a healthy vagina. L. acidophilus produces hydrogen peroxide V (as a by-product of metabolism), which is toxic to pathogens and keeps the healthy vaginal pH acidic. Alterations of the vaginal micro flora by invading pathogens or biochemical changes in the environment results in vaginitis \hyperref[b40]{(Odds, 2008)}.\par Changes in the vaginal environment, Candida population, and their adherence to vaginal epithelial cells enhance the germination of daughter yeast cells \hyperref[b55]{(Sobel, 2007)}. These changes and attendant multiplication of Candida cells may transform asymptomatic colonization into symptomatic infection. VVC, like many vulva diseases, has the potential to cause psychological distress and negatively impact patient's quality of life. \section[{a) Aim of the Study}]{a) Aim of the Study}\par Our study aims to assess the level of urethritis due to Candida albicans amongst undergraduate students of Chukwuemeka Odumegu Ojukwu University, Uli.\par b) Specific Objectives -Determination of the prevalence of candidiasis amongst undergraduate students -Correlation of the prevalence rates with age, sex, and other risk factors -Evaluating the effects of predisposing factors on both symptomatic and asymptomatic persons. \section[{c) Significance of the Study}]{c) Significance of the Study}\par Fungal infections of the urinary tract especially, those caused by Candida albicans are becoming increasingly common. Urethritis due to Candida is mostly misdiagnosed or undiagnosed, as most studies concentrate on the bacterial urinary tract infections. Studies on the epidemiology of fungal urinary tract infections are limited in apparently healthy individuals since most studies were carried out in the hospital settings amongst hospitalized patients. There are few studies that provide good databases for guiding public health practitioners on the diagnostic criteria and therapeutic pathways. \section[{d) Limitation of the Study}]{d) Limitation of the Study}\par The study population was undergraduate students. This made the research participants selective. Collection of urine samples from students was burdensome due to the misconceptions and fear of societal ills.\par Some students refused to fill the questionnaires. \section[{II. Materials and Methods}]{II. Materials and Methods} \section[{a) Study Population}]{a) Study Population}\par One hundred students of Chukwuemeka Odumegwu Ojukwu University, Uli were randomly selected for this research. Only undergraduate students in regular programs were used. Consent was obtained from the participants. \section[{b) Sampling Procedures i. Administration of questionnaires}]{b) Sampling Procedures i. Administration of questionnaires}\par We obtained baseline socio demographic data using well-structured questionnaires and ensured confidentiality amongst the respondents.\par ii. Collection of urine samples We gave well-labeled sterile wide-mouthed screw-capped plastic containers with the same unique numbers as written on the questionnaires to the respondents. Each student was instructed on how to collect clean-catch midstream urine sample. 10 ml was obtained from each student. \section[{iii. Media used}]{iii. Media used}\par Sabouraud dextrose agar (SDA) and cornmeal agar (CMA) were used. \section[{c) Culture and Identification of Candida albicans}]{c) Culture and Identification of Candida albicans}\par Sterile cornmeal agar plates were inoculated with the urine specimens and incubated at 25 o C for 72 hours. Each plate was read daily, recording the colony size, color and shapes. The isolates were subsequently streaked on sterile Sabouraud dextrose agar plates and incubated at 30 o C for 4days. The pure cultures were Gram-stained and observed microscopically using x100 oil immersion objective (WHO, 2003).\par i \section[{. Germ tube test}]{. Germ tube test}\par The pure cultures were suspended in test tubes containing 0.5ml human serum. These were incubated at 35 o Cfor 2 hours. A drop of the yeast-serum suspension was placed on a microscope slide and overlaid with a coverslip. This was examined microscopically for the presence of Germ tubes \hyperref[b59]{(Winn et al., 2006)}. \section[{III. Results}]{III. Results}\par We present the socio-demographic characteristics of the study subjects in Table \hyperref[tab_0]{1}. Of the 100 students examined, 80(80.0\%) were female and 20(20.0\%) were male. Only 8 of the sampled students were married, none was pregnant. Of the sampled students 11(11.0\%) knew about urinary tract infection, but only 7(7.0\%) had history of urinary tract infection (previously suffered from it). 17\% were symptomatic whereas the remaining 83\% were asymptomatic. More so, 17(77.2\%) students had used antibiotics either by prescription or self-medication, 5(22.7\%) said they have not used it.\par 14 had Candida positive cultures making the prevalence of vulvovaginal candidiasis 14.0\%. Candida positive cultures were observed mostly among ages 21-30 years {\ref [11(11.0\%)}]. The majority of students in this age group were in their third to final year and are sexually active. The prevalence of infection between the age groups was statistically not significant (P> 0.05). Therefore, there is no significant difference between the age groups. Out of the 100 urine samples cultured, 14 showed Candida growth, and the 14 were from female students. The prevalence of infection between the sexes was statistically not significant (P> 0.05). Therefore, there is no significant difference between sexes. IV. Discussion\par Our study found the prevalence of vaginal candidiasis amongst undergraduate students of Chukwuemeka Odumegwu Ojukwu University, Uli, Nigeria to be 14\%. Our result is lower than that reported by Aringet al. {\ref (2012)}. In their study the prevalence of candidiasis was 16.5\%, 21.31\%, and 19 \% respectively.\par The relatively low prevalence we observed may be attributed to adequate knowledge, good personal hygiene, and normal levels of estrogens and corticoids amongst undergraduate students. Our result is however, in agreement with the studies of Fernández et al. {\ref (2004)}.\par We observed candidiasis in students between ages 20 -30 {\ref [} There was no statistically significant relationship between the prevalence of VVC with age (P>0.05) or clinical symptoms of ill health (P>0.05). This may be due to recurrent infections that might have contributed to the resistance of the vagina to candidiasis. Subjects with vulvovaginal discomfort had a higher percentage of Candida-positive cultures (29.1\%) than those with no vulvovaginal discomfort (11.9\%). This report is in agreement with the findings of \hyperref[b23]{Jombo et al. (2010)}. It is reasonable to believe that young women with genital discomfort consult health care centers more often than women without such symptoms \hyperref[b23]{(Jombo et al., 2010)}.\par All subjects with positive Candida culture results had already been on antibacterial therapy prior to their hospital visit -28 (100\%). This finding is in conformity with the fact that prolonged antibacterial use usually affects vaginal bacteria micro flora population and biochemical activity (mainly L. acidophilus), which thus increases vaginal pH as a result of reduced CO 2 production. This feature, alongside other factors (such as hormonal factors), encourages Candida overgrowth, consequently leading to vulvovaginitis \hyperref[b5]{(Bauters et al., 2002)}.\par Although the widespread use of antibiotics has been suggested as one of the major factors contributing to the rising incidence of VVC, \hyperref[b18]{(Foxman et al.,2008)}some case-control studies \hyperref[b19]{(Geiger et al.,2006)} found no evidence of an association between antibiotic agents and symptomatic VCC, whereas others reached the opposite conclusion \hyperref[b57]{(Spinillo et al.,2009}). \section[{V. Conclusion}]{V. Conclusion}\par There is a need to create awareness of the involvement of Candida spp. in genital discomfort, especially vaginal candidiasis, amongst undergraduate students with or without notable signs and symptoms. It is worthwhile to consider culture test as adjunctive in combination with clinical symptoms in the definitive diagnosis of VVC. More work is required to build on findings generated from this study. \section[{VI. Recommendations}]{VI. Recommendations}\par We recommend the following:\par ? The presence of candidiasis among apparently healthy individuals should not be neglected. \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.85\textwidth}} Gender\end{longtable} \par \caption{\label{tab_0}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.3069444444444444\textwidth}P{0.16527777777777777\textwidth}P{0.14166666666666666\textwidth}P{0.2361111111111111\textwidth}} Age (years)\tabcellsep No. Examined\tabcellsep No. Positive\tabcellsep Prevalence(\%)\\ 15-20\tabcellsep 7\tabcellsep 3\tabcellsep 3.0\\ 21-25\tabcellsep 54\tabcellsep 6\tabcellsep 6.0\\ 26-30\tabcellsep 37\tabcellsep 5\tabcellsep 5.0\\ Above 30\tabcellsep 2\tabcellsep 0\tabcellsep 0.0\\ Total\tabcellsep 100\tabcellsep 14\tabcellsep 14.0\end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.23398876404494381\textwidth}P{0.2101123595505618\textwidth}P{0.18146067415730335\textwidth}P{0.224438202247191\textwidth}} Clinical presentation\tabcellsep No. examined\tabcellsep No. positive\tabcellsep Prevalence\\ Symptomatic\tabcellsep 17(17.0\%)\tabcellsep 4(28.6)\tabcellsep 23.5(66.2\%)\\ Asymptomatic\tabcellsep 83(83.0\%)\tabcellsep 10(71.4)\tabcellsep 12.0(33.8\%)\\ Total\tabcellsep 100(100.0\%)\tabcellsep 14(100.0\%)\tabcellsep 35.5(100.0\%)\end{longtable} \par \caption{\label{tab_2}Table 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_3}}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.85\textwidth}} D D D D ) C\\ (\end{longtable} \par \caption{\label{tab_4}}\end{figure} \footnote{© 2020 Global JournalsPrevalence of Candidiasis amongst Undergraduate Students of COOU, Uli, Nigeria} \backmatter \begin{bibitemlist}{1} \bibitem[Silva et al. ()]{b52}\label{b52} ‘Adherence and biofilm formation of non-Candida albicans Candida species’. S Silva , M Negri , M Henriques , R Oliveira , D W Williams , J Azeredo . \textit{Trends in} 2011. 19 p. . \bibitem[Corsello et al. ()]{b9}\label{b9} ‘An epidemiological surgery of vulvovaginal candidiasis in Italy’. S Corsello , A Spinillo , G Osnengo . \textit{European Journal of Obstetrics, Gynecology, and Reproductive} 2003. 110 (1) p. . \bibitem[Kett et al. ()]{b26}\label{b26} ‘Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis’. D H Kett , A F Shorr , A C Reboli . \textit{Critical} 2011. 15 (5) p. 253. \bibitem[Akortha et al. ()]{b1}\label{b1} ‘Antifungal resistance among Candida species from patients with genitourinary tract infection isolated in Benin City, Edo estate’. E Akortha , O Chikwe , O Nwaugo . \textit{Nigeria. African Journal of Microbiological Research} 2009. 3 (11) p. . \bibitem[Hasan et al. ()]{b20}\label{b20} ‘Biofilm formation in clinical Candida isolates and its association with virulence’. F Hasan , I Xess , X Wang , N Jain , B C Fries . \textit{Microbes and Infection} 2009. (11) p. . \bibitem[Odds ()]{b40}\label{b40} \textit{Candida and Candidiasis: A Review and Bibliography. Second Edition}, F C Odds . 2008. London: Bailliere Tindall Press. p. . \bibitem[Fidel ()]{b17}\label{b17} ‘Candida-host interactions in Human Immune Deficiency Virus disease: relationships in or opharyngeal candidiasis’. P L Fidel . \textit{Advances in Dental} 2006. 19 p. . \bibitem[Martins et al. ()]{b32}\label{b32} \textit{Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment}, N Martins , I C Ferreira , L Barros , S Silva , M Henriques . 2014. 177 p. . \bibitem[Nyirjesy ()]{b38}\label{b38} ‘Chronic vulvovaginal candidiasis’. P Nyirjesy . \textit{American Family} 2001. 63 (4) p. . \bibitem[Eschenbach ()]{b14}\label{b14} ‘Chronic vulvovaginal candidiasis’. D A Eschenbach . \textit{The New England Journal} 2004. 351 (9) p. . \bibitem[Pappas et al. ()]{b43}\label{b43} ‘Clinical Practice Guideline for the Management of Candidiasis’. P G Pappas , C A Kauffman , D R Andes , C J Clancy , K A Marr , Z L Ostrosky . \textit{Clinical Infectious} 2016. 62 (4) p. . \bibitem[Pappas et al. ()]{b44}\label{b44} ‘Clinical practice guidelines for the management of candidiasis’. P G Pappas , C A Kauffman , D Andes , D K Benjamin , T F Calandra , J E Edwards . \textit{Clinical Infectious} 2009. 48 (5) p. . \bibitem[Kauffman ()]{b24}\label{b24} ‘Diagnosis and management of fungal urinary tract infection’. C A Kauffman . \textit{Infectious Disease Clinics of North} 2013. 28 (1) p. . \bibitem[Reed et al. ()]{b49}\label{b49} ‘Differentiation of Gardnerella vaginalis, Candida albicans, and Trichomonas vaginalis infections of the vagina’. B D Reed , W Huck , P Zazove . \textit{The Journal of Family} 2009. 28 (6) p. . \bibitem[Spinillo et al. ()]{b57}\label{b57} ‘Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis’. A Spinillo , E Capuzzo , S Acciano , A De Santolo , F Zara . \textit{American Journal of Obstetrics} 2009. 180 (1) p. . \bibitem[Paul et al. ()]{b46}\label{b46} ‘Effects of reproductive hormones on experimental vaginal Candidiasis’. L F Paul , C Jessica , S Chad . \textit{Journal of Infection} 2000. 68 (2) p. . \bibitem[Horn et al. ()]{b21}\label{b21} ‘Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry’. D L Horn , D Neofytos , E J Anaissie , J A Fishman , W J Steinbach , A J Olyaei , K A Marr , M A Pfaller , C H Chang , K M Webster . \textit{Clinical Infectious Diseases} 2009. (48) p. . \bibitem[Foxman et al. ()]{b18}\label{b18} ‘Frequency and response to vaginal symptoms among white and African American women: results of a random digit dialing survey’. B Foxman , J V Marsh , B Gillespie , J D Sobel . \textit{Journal of Women} 2008. 7 (9) p. . \bibitem[Pappas et al. ()]{b45}\label{b45} ‘Guidelines for treatment of candidiasis’. P G Pappas , J H Rex , J D Sobel . \textit{Clinical Infectious Diseases} 2004. 38 (2) p. . \bibitem[Andes et al. ()]{b3}\label{b3} ‘Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis’. D R Andes , N Safdar , J W Baddley , G Playford , A C Reboli , J H Rex . \textit{Clinical Infectious Diseases} 2012. 54 (8) p. . \bibitem[Aring et al. ()]{b4}\label{b4} ‘Incidence of vaginal candidiasis in leucorrhoea in women attending in orthopedic of gynecology and obstetrics department’. B J Aring , P J Mankodi , J H Jasani . \textit{International Journal of Biomedical and Advanced} 2012. 3 (12) p. . \bibitem[Winn et al. ()]{b59}\label{b59} \textit{Koneman's Color Atlas and Textbook of Diagnostic Microbiology}, W C Winn , S D Allen , W M Janda , E W Koneman , G W Procop , P C Schreckenberger , G L Woods . 2006. United States of America: Lippincott Williams and Welkins Press. p. . (Sixth Edition) \bibitem[Das-Neves et al. ()]{b11}\label{b11} \textit{Local treatment of vulvovaginal candidosis: general and practical considerations}, J Das-Neves , E Pinto , B Teixeira , G Dias , P Rocha , T Cunha . 2008. 68 p. . \bibitem[Sobel ()]{b54}\label{b54} ‘Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis’. J D Sobel . \textit{N Engl J Med} 2004. 351 (9) p. . \bibitem[Martini et al. ()]{b31}\label{b31} F C Martini , W C Ober , C W Garrison , K Welch , R T Hutchings . \textit{Fundamentals of Anatomy and Physiology. Fifth Edition}, (Prentice-Hall Eaglewood Cliffs, United States of America) 2001. p. . \bibitem[Chandrasekar and Sobel ()]{b8}\label{b8} ‘Micafungin: a new echinocandin’. P H Chandrasekar , J D Sobel . \textit{Clinical Infectious} 2006. 42 (8) p. . \bibitem[Lewis and Candida (2013)]{b29}\label{b29} ‘New Rapid Blood Test Could Cut Mortality’. R Lewis , Candida . \url{http://www.medscape.com/viewarticle/803135.Accessed} \textit{Medscape Medical News} Apr 25 2013. Apr 30, 2013. \bibitem[Kerawala and Newlands ()]{b25}\label{b25} \textit{Oral and maxillofacial surgery}, C Kerawala , C Newlands . 2010. London: Oxford University Press. p. . \bibitem[Ferris et al. ()]{b16}\label{b16} ‘Over-thecounter antifungal drug misuse associated with patient diagnosed vulvovaginal candidiasis’. D G Ferris , P Nyirjesy , J D Sobel , D Soper , A Pavletic , M S Litaker . \textit{Obstetrics} 2002. 99 (3) p. . \bibitem[Rex et al. ()]{b50}\label{b50} ‘Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America’. J H Rex , T J Walsh , J D Sobel . \textit{Clinical Infectious} 2000. 30 (4) p. . \bibitem[De Leon et al. ()]{b12}\label{b12} ‘Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes’. E M De Leon , S J Jacober , J D Sobel , B Foxman . \textit{Bio Med Central Infectious Diseases2} 2002. \bibitem[Alo et al. ()]{b2}\label{b2} ‘Prevalence of asymptomatic co-infection of Candidiasis and vaginal Trichomonas among pregnant women in Abakaliki’. M N Alo , C Anyim , A K Onyebuchi , E C Okonkwo . \textit{Journal of Natural Sciences} 2012. 2 (7) p. . \bibitem[Akinbiyi et al. ()]{b0}\label{b0} ‘Prevalence of Candidaalbicans and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire’. A A Akinbiyi , R Watson , W P Feyi . \textit{United Kingdom. Archive of Gynecology} 2008. 278 p. . \bibitem[Ray et al. ()]{b47}\label{b47} ‘Prevalence of Candidaglabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis’. D Ray , R Goswami , U Banerjee . \textit{Diabetes} 2007. 30 (2) p. . \bibitem[Nelson et al. ()]{b35}\label{b35} ‘Prevalence of vaginal candidiasis and determination of the occurrence of Candida species in pregnant women attending the antenatal clinic of Thika District Hospital’. M Nelson , W Wanjiru , M W Margaret . \textit{Kenya. Open Journal of Medical Microbiology} 2013. (3) p. . \bibitem[Bauters et al. ()]{b5}\label{b5} ‘Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women’. T G Bauters , M A Dhont , M I Temmerman , H J Nelis . \textit{American Journal of Obstetrics and Gynecology} 2002. 187 (3) p. . \bibitem[Mcclelland et al. ()]{b33}\label{b33} ‘Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis’. R S Mcclelland , B A Richardson , W M Hassan . \textit{Journal of Infectious} 2009. 199 (12) p. . \bibitem[Ingham et al. ()]{b22}\label{b22} ‘Rapid susceptibility testing and microcolony analysis of Candida species cultured and imaged on porous aluminum oxide’. C J Ingham , S Boonstra , S Levels , M De Lange , J F Meis , P M Schneeberger . \textit{Journal of Public} 2012. 1 (7) p. . \bibitem[Nandan et al. ()]{b34}\label{b34} ‘Reproductive tract infection in women of reproductive age group in Sitapur/ Shahjahanpur district of Uttar Pradesh’. D Nandan , Y P Gupta , V Krishnan , A Sharma , S K Misra . \textit{Indian Journal of Public} 2011. 5 (1) p. . \bibitem[Reed ()]{b48}\label{b48} ‘Risk factors for Candida vulvovaginitis’. B D Reed . \textit{Obstetrical and Gynecological} 2002. 47 (8) p. . \bibitem[Geiger and Foxman ()]{b19}\label{b19} \textit{Risk factors for vulvovaginal candidiasis: a case-control study among university students}, A M Geiger , B Foxman . 2006. 7 p. . \bibitem[Erdogan and Rao ()]{b13}\label{b13} ‘Small intestinal fungal overgrowth’. A Erdogan , S S Rao . \textit{Current Gastroenterology} 2015. 17 (4) p. 16. \bibitem[Nohmi et al. ()]{b36}\label{b36} ‘Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro: A possible mechanism in pregnant women's vulnerability to vaginal candidiasis’. T Nohmi , S Abe , K Dobashi , S Tansho , H Yamaguchi . \textit{Microbiology and Immunology} 2005. (39) p. . \bibitem[Jombo et al. ()]{b23}\label{b23} ‘Symptomatic vulvovaginal candidiasis and genital colonization by Candida species in Nigeria’. G T Jombo , S O Opajobi , D Z Egah , E B Banwat , A P Denen . \textit{Journal of Public Health} 2010. 2 (6) p. . \bibitem[Okungbowa et al. ()]{b41}\label{b41} ‘The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigeria cities’. F I Okungbowa , O S Isuehuemhen , A Dede . \textit{Revista Iberoamericana de Micologia} 2003. (20) p. . \bibitem[Spinillo et al. ()]{b56}\label{b56} ‘The impact of oral contraception on vulvovaginal candidiasis’. A Spinillo , E Capuzzo , S Nicola , F Baltaro , A Ferrari , A Monaco . \textit{Contraception} 2005. 51 (5) p. . \bibitem[Leegaard ()]{b28}\label{b28} ‘The incidence of Candida albicans in the vagina of "healthy young women". How often do they have symptoms? Possible etiological factors’. M Leegaard . \textit{Acta Obstetricia Et Gynecologica} 2004. 63 (1) p. . \bibitem[Cullen and Sprague ()]{b10}\label{b10} \textit{The regulation of filamentous growth in yeast}, P J Cullen , G F Sprague . 2012. 190 p. . \bibitem[Lai et al. ()]{b27}\label{b27} ‘Time to positivity of blood cultures of different Candida species causing fungaemia’. C C Lai , C Y Wang , W L Liu , Y T Huang , P R Hsueh . \textit{Journal of Medical Microbiology} 2012. (61) p. . \bibitem[Ringdahl ()]{b51}\label{b51} ‘Treatment of recurrent vulvovaginal candidiasis’. E Ringdahl . \textit{American Family} 2000. 61 (11) p. . \bibitem[Singh ()]{b53}\label{b53} ‘Treatment of vulvovaginal candidiasis’. S I Singh . \textit{Clinical Reviews} 2003. 136 (9) p. . \bibitem[Willacy and Jackson (2011)]{b58}\label{b58} \textit{Vaginal and vulval candidiasis}, H Willacy , C Jackson . \url{http://www.patient.co.uk/doctor/vaginal-and-vulval-candidiasis} 2011. May 17. 2015. \bibitem[Nwadioha et al. ()]{b37}\label{b37} ‘Vaginal candidiasis and its risk factors among women attending a Nigerian teaching hospital’. S I Nwadioha , E O Nwokedi , J Egesie , H Enejuo . \textit{Nigerian Postgraduate Medical Journal} 2013. (20) p. . \bibitem[Cauwenbergh ()]{b7}\label{b7} ‘Vaginal candidiasis: evolving trends in the incidence and treatment of non-Candida albicans infection. Current Problems in Obstetrics’. G Cauwenbergh . \textit{Gynecology and Fertility8}, 2000. p. 241. \bibitem[Ferrer ()]{b15}\label{b15} ‘Vaginal candidosis: epidemiological and etiological factors’. J Ferrer . \textit{International Journal of Gynecology} 2000. 71 (1) p. . \bibitem[Calderone and Fonzi ()]{b6}\label{b6} ‘Virulence factors of Candida albicans’. R A Calderone , W A Fonzi . \textit{Trends in} 2001. 9 p. . \bibitem[Marrazzo ()]{b30}\label{b30} ‘Vulvovaginal candidiasis’. J Marrazzo . \textit{British Medical} 2002. 3 (4) p. . \bibitem[Nyirjesy and Sobel ()]{b39}\label{b39} ‘Vulvovaginal candidiasis’. P Nyirjesy , J D Sobel . \textit{Obstetrics and Gynecology Clinics of North} 2003. 30 (4) p. . \bibitem[Omar ()]{b42}\label{b42} ‘Vulvovaginal candidiasis among women in makkah city, Saudi Arabia’. A A Omar . \textit{Research Journal of Medical} 2001. 7 (4) p. . \bibitem[Sobel ()]{b55}\label{b55} ‘Vulvovaginal candidosis’. J D Sobel . \textit{The} 2007. 369 p. . \end{bibitemlist} \end{document}